Durolane SJ for Treatment of Rhizarthrosis
Primary Purpose
Rhizarthrosis
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Durolane SJ
Sponsored by

About this trial
This is an interventional treatment trial for Rhizarthrosis
Eligibility Criteria
Inclusion Criteria:
- Subjects of both sexes aged 18 to 75 years.
- Diagnosis of Grade II-III rhizarthrosis in either hand, according to the criteria of Eaton and Littler.
- TMC joint pain lasting longer than 6 months and baseline pain value greater than or equal to 4 on the VAS scale (0 to 10) and less than 4 in the contralateral hand joint if there is pain.
Exclusion Criteria:
- Anticoagulant medication
- Rheumatic disease involving the wrist, hand and fingers, such as rheumatoid arthritis or gout
- Active rheumatoid arthritis
- Previous surgery of the hand
- Systemic infectious processes
- Neoplastic disease
- Subjects with contraindications to hyaluronic acid
- Subjects with known hypersensitivity to hyaluronic acid or any of the components of the preparation under study
- Previous hyaluronic acid injections in the hand
- Subjects likely to miss the clinical follow-up visits
- Taking of analgesics 24 hours before scheduled clinical assessments
- Pregnant subjects
- Any condition that in the opinion of the physician recommends exclusion of the subject
Sites / Locations
- Hospital Sant Joan Despi Moises Broggi
- Hospital Universitari Vall d'Hebron
- Corporació Sanitària Parc Taulí
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Durolane SJ
Arm Description
single dose injection. One infiltration of the study product in the trapeziometacarpal (TMC) joint. The study treatment contains sodium hyaluronate 20 mg/mL, in a 1 mL prefilled syringe.
Outcomes
Primary Outcome Measures
Change From Baseline in Pain Measured by the VAS Scale
Visual Analogue Scale (VAS) pain in injected hand. The VAS scale ranges from 0 cm (least pain) to 10 cm (most pain).
A Visual Analogue Scale (VAS) is a measurement instrument that measures a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
Secondary Outcome Measures
Change From Baseline in Biomechanical Function, Measured by the Quick DASH Questionnaire
The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire is a 30-item questionnaire that looks at the ability of a patient to perform certain upper extremity activities.This is a self-report questionnaire that patients can use to rate difficulty and interference with daily life. Quick DASH questionnaire is a shortened version of the DASH Outcome Measure which uses 11 items to measure physical function and symptoms in people with musculoskeletal disorders of the upper limb. Possible scores range from 11-55, which can be remapped to a 0-100 scale. This latter ranges from 0 units (most functionality) to 100 units (least functionality).
Full Information
NCT ID
NCT02676284
First Posted
January 20, 2016
Last Updated
December 2, 2021
Sponsor
Zambon SAU
Collaborators
Bioventus LLC
1. Study Identification
Unique Protocol Identification Number
NCT02676284
Brief Title
Durolane SJ for Treatment of Rhizarthrosis
Official Title
Study of the Clinical and Biomechanical Effectiveness of Durolane SJ in Rhizarthrosis
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zambon SAU
Collaborators
Bioventus LLC
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main objective of the trial is to assess the clinical changes in terms of physical examination, VAS Scale and the Quick-DASH questionnaire, and the biomechanical parameters in terms of mobility of the TMC joint, the grip strength of the hand and lateral pinch strength in patients with rhizarthrosis after administration of viscosupplementation.
The secondary objectives of the trial will be to assess the safety of the treatment with viscosupplementation, and the correlation between the clinical and biomechanical changes at the end of the trial.
Detailed Description
This is a prospective, open, non-comparative study in 36 subjects with rhizarthrosis, comparing signs and symptoms before and after a single injection of DUROLANE SJ in the affected hand.
Subjects were assessed pre-treatment and at 1, 3, and 6 months post-treatment. This study is associated with a post marketing commitment with the European Notified Body, BSI, to confirm DUROLANE SJ's effectiveness in rhizarthrosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rhizarthrosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Durolane SJ
Arm Type
Experimental
Arm Description
single dose injection. One infiltration of the study product in the trapeziometacarpal (TMC) joint. The study treatment contains sodium hyaluronate 20 mg/mL, in a 1 mL prefilled syringe.
Intervention Type
Device
Intervention Name(s)
Durolane SJ
Intervention Description
DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
Primary Outcome Measure Information:
Title
Change From Baseline in Pain Measured by the VAS Scale
Description
Visual Analogue Scale (VAS) pain in injected hand. The VAS scale ranges from 0 cm (least pain) to 10 cm (most pain).
A Visual Analogue Scale (VAS) is a measurement instrument that measures a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
Time Frame
Baseline and 26 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Biomechanical Function, Measured by the Quick DASH Questionnaire
Description
The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire is a 30-item questionnaire that looks at the ability of a patient to perform certain upper extremity activities.This is a self-report questionnaire that patients can use to rate difficulty and interference with daily life. Quick DASH questionnaire is a shortened version of the DASH Outcome Measure which uses 11 items to measure physical function and symptoms in people with musculoskeletal disorders of the upper limb. Possible scores range from 11-55, which can be remapped to a 0-100 scale. This latter ranges from 0 units (most functionality) to 100 units (least functionality).
Time Frame
Baseline and 26 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects of both sexes aged 18 to 75 years.
Diagnosis of Grade II-III rhizarthrosis in either hand, according to the criteria of Eaton and Littler.
TMC joint pain lasting longer than 6 months and baseline pain value greater than or equal to 4 on the VAS scale (0 to 10) and less than 4 in the contralateral hand joint if there is pain.
Exclusion Criteria:
Anticoagulant medication
Rheumatic disease involving the wrist, hand and fingers, such as rheumatoid arthritis or gout
Active rheumatoid arthritis
Previous surgery of the hand
Systemic infectious processes
Neoplastic disease
Subjects with contraindications to hyaluronic acid
Subjects with known hypersensitivity to hyaluronic acid or any of the components of the preparation under study
Previous hyaluronic acid injections in the hand
Subjects likely to miss the clinical follow-up visits
Taking of analgesics 24 hours before scheduled clinical assessments
Pregnant subjects
Any condition that in the opinion of the physician recommends exclusion of the subject
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eloisa Velasco Ruiz, MD
Organizational Affiliation
Hospital Sant Joan Despi Moises Broggi
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Sant Joan Despi Moises Broggi
City
Sant Joan Despí
State/Province
Barcelona
ZIP/Postal Code
08970
Country
Spain
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Corporació Sanitària Parc Taulí
City
Barcelona
ZIP/Postal Code
08208
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Durolane SJ for Treatment of Rhizarthrosis
We'll reach out to this number within 24 hrs